Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Carl Barrett

Showing results (171-180 of 210) with videos related to

Pageof 21
Sort By:
The Lancet. Oncology|December 8, 2014
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trialAmit M Oza, David Cibula, Ana Oaknin Benzaquen, et al.
Endocrinology|September 9, 2006
Increased tumor growth in mice with diet-induced obesity: impact of ovarian hormonesShoshana Yakar, Nomeli P Nunez, Patricia Pennisi, et al.
JCO Precision Oncology|May 28, 2026
Human Epidermal Growth Factor Receptor 2 Quantification Using Computational Pathology to Identify Novel Biomarkers for Trastuzumab Deruxtecan-Treated Human Epidermal Growth Factor Receptor 2-Positive Gastric CancerAnsh Kapil, Henrik Failmezger, Yu Fu, et al.
British Journal of Cancer|October 25, 2018
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genesDarren R Hodgson, Brian A Dougherty, Zhongwu Lai, et al.
JCO Precision Oncology|July 12, 2021
Validation of ctDNA Quality Control Materials Through a Precompetitive Collaboration of the Foundation for the National Institutes of HealthP Mickey Williams, Thomas Forbes, Steven P Lund, et al.
Cancer Research|September 6, 2005
Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cellsJulie A Hong, Yang Kang, Ziedulla Abdullaev, et al.
Clinical Chemistry|September 2, 2020
Generic Protocols for the Analytical Validation of Next-Generation Sequencing-Based ctDNA Assays: A Joint Consensus Recommendation of the BloodPAC's Analytical Variables Working GroupJames H Godsey, Angela Silvestro, J Carl Barrett, et al.
Molecular Cancer|May 29, 2024
Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 studyMingchao Xie, Miljenka Vuko, Jaime Rodriguez-Canales, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 18, 2020
<i>STAT3</i> Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti-PD-L1Theresa A Proia, Maneesh Singh, Richard Woessner, et al.
Cancer Cell|December 8, 2009
A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2Samuel C Mok, Tomas Bonome, Vinod Vathipadiekal, et al.
Pageof 21

Showing results (171-180 of 210) with videos related to

Sort By:
Pageof 21
The Lancet. Oncology|December 8, 2014
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trialAmit M Oza, David Cibula, Ana Oaknin Benzaquen, et al.
Endocrinology|September 9, 2006
Increased tumor growth in mice with diet-induced obesity: impact of ovarian hormonesShoshana Yakar, Nomeli P Nunez, Patricia Pennisi, et al.
JCO Precision Oncology|May 28, 2026
Human Epidermal Growth Factor Receptor 2 Quantification Using Computational Pathology to Identify Novel Biomarkers for Trastuzumab Deruxtecan-Treated Human Epidermal Growth Factor Receptor 2-Positive Gastric CancerAnsh Kapil, Henrik Failmezger, Yu Fu, et al.
British Journal of Cancer|October 25, 2018
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genesDarren R Hodgson, Brian A Dougherty, Zhongwu Lai, et al.
JCO Precision Oncology|July 12, 2021
Validation of ctDNA Quality Control Materials Through a Precompetitive Collaboration of the Foundation for the National Institutes of HealthP Mickey Williams, Thomas Forbes, Steven P Lund, et al.
Cancer Research|September 6, 2005
Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cellsJulie A Hong, Yang Kang, Ziedulla Abdullaev, et al.
Clinical Chemistry|September 2, 2020
Generic Protocols for the Analytical Validation of Next-Generation Sequencing-Based ctDNA Assays: A Joint Consensus Recommendation of the BloodPAC's Analytical Variables Working GroupJames H Godsey, Angela Silvestro, J Carl Barrett, et al.
Molecular Cancer|May 29, 2024
Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 studyMingchao Xie, Miljenka Vuko, Jaime Rodriguez-Canales, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 18, 2020
<i>STAT3</i> Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti-PD-L1Theresa A Proia, Maneesh Singh, Richard Woessner, et al.
Cancer Cell|December 8, 2009
A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2Samuel C Mok, Tomas Bonome, Vinod Vathipadiekal, et al.
Pageof 21